Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
-34.21%
↓ 121% vs avg
Percentile
P26
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
164.22%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -34.21% |
| Q3 2025 | 113.24% |
| Q2 2025 | -133.63% |
| Q1 2025 | 414.52% |
| Q4 2024 | -6.60% |
| Q3 2024 | -18.89% |
| Q2 2024 | -24.94% |
| Q1 2024 | 21.61% |
| Q4 2023 | -366.56% |
| Q3 2023 | -21.56% |
| Q2 2023 | 34.40% |
| Q1 2023 | 58.06% |
| Q4 2022 | -9.97% |
| Q3 2022 | 0.22% |
| Q2 2022 | -209.70% |
| Q1 2022 | 202.32% |
| Q4 2021 | -154.21% |
| Q3 2021 | 18.55% |
| Q2 2021 | -111.22% |
| Q1 2021 | 777.95% |
| Q4 2020 | -258.73% |
| Q3 2020 | 67.54% |
| Q2 2020 | -21.17% |
| Q1 2020 | -17.23% |
| Q4 2019 | -270.38% |
| Q3 2019 | 31.19% |
| Q2 2019 | 153.74% |
| Q1 2019 | -111.64% |
| Q4 2018 | 6378.54% |
| Q3 2018 | 81.40% |
| Q2 2018 | 6.70% |
| Q1 2018 | -5.13% |
| Q4 2017 | -59.62% |
| Q3 2017 | 11.59% |
| Q2 2017 | 27.34% |
| Q1 2017 | -243.26% |
| Q4 2016 | 198.22% |
| Q3 2016 | 44.52% |
| Q2 2016 | -24.43% |
| Q1 2016 | 30.26% |